Asthma

MD IQ

News from the FDA/CDC

Benralizumab approved for eosinophilic asthma

Compared with placebo, benralizumab reduced the annual asthma exacerbation rate in eosinophilic asthma patients by up to 51%.

Conference Coverage

Omalizumab helps asthma COPD overlap patients

Researchers presented the findings of a study of one of the largest observational cohorts to date of patients with asthma COPD overlap (ACO) at...

Pages